Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 11/20 | 0.54 |
| ▸ | PLK3 | Q9H4B4 | 6/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | METAP2 | P50579 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 2/20 | 0.46 |
| ▸ | RARA | P10276 | 1/20 | 0.46 |
| ▸ | RARG | P13631 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16127895 | 0.89 | MAPT (0.50) | PLK1PLK3GAAL3MBTL1MAPT | |
| SCHEMBL16088649 | 0.89 | METAP2 (0.62) | PLK1PLK3METAP2 | |
| SCHEMBL23864558 | 0.88 | PLK1 (0.44) | PLK1PLK3GAAL3MBTL1METAP2 | |
| SCHEMBL16088633 | 0.85 | PLK1 (0.54) | PLK1PLK3METAP2 | |
| SCHEMBL16088691 | 0.83 | KMT2A (0.61) | PLK1PLK3GAAL3MBTL1METAP2 | |
| SCHEMBL17531732 | 0.83 | PLK1 (0.49) | PLK1PLK3GAAL3MBTL1METAP2 | |
| SCHEMBL16088619 | 0.82 | PLK1 (0.51) | PLK1PLK3METAP2 | |
| SCHEMBL16088652 | 0.82 | PLK1 (0.48) | PLK1PLK3GAAL3MBTL1METAP2 | |
| SCHEMBL16088611 | 0.78 | KMT2A (0.58) | GAAL3MBTL1MAPTALDH1A1 | |
| SCHEMBL7821783 | 0.77 | MAPT (0.74) | GAAL3MBTL1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452170-B2 | Compounds and methods for inducing chondrogenesis | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160045514-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-02-18 | — | — | US | disclosed |
| US-20140271955-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045514-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | COL2A1, BMP4, COL1A1 | PLK1 1776/4885PLK3 3998/4885GAA 2935/4885 |
| US-20140271955-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | COL2A1, BMP4, COL1A1 | PLK1 1776/4885PLK3 3998/4885GAA 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.